½ÃÀ庸°í¼­
»óǰÄÚµå
1751518

¼¼°èÀÇ µ¿¹° ÀÇ·á¿ë ´ÜÀÏŬ·ÐÇ×ü ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¿ëµµº°, µ¿¹° À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)

Monoclonal Antibodies In Veterinary Health Market Size, Share & Trends Analysis Report By Application (Dermatology, Pain), By Animal Type (Dogs), By End User (Veterinary Hospitals), By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

µ¿¹° ÀÇ·á¿ë ´ÜÀÏŬ·ÐÇ×ü ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, µ¿¹° ÀÇ·á¿ë ´ÜÀÏŬ·ÐÇ×ü ¼¼°è ½ÃÀå ±Ô¸ð´Â 2025-2030³â ¿¬Æò±Õ 19.1%ÀÇ ¼ºÀå·ü·Î È®´ëµÇ¾î 2030³â¿¡´Â 33¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¹Ý·Áµ¿¹° ¼ö Áõ°¡¿Í ¹Ý·Áµ¿¹°¿¡ ´ëÇÑ ÁöÃâ Áõ°¡°¡ °áÇÕÇÏ¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ, °³ ¾ÆÅäÇÇ ÇǺο°ÀÇ À¯º´·ü Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

Äڷγª19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ È¥¶õ¿¡µµ ºÒ±¸ÇÏ°í µ¿¹°¿ëÀǾàǰ »ê¾÷Àº 2019³âºÎÅÍ 2020³â±îÁö 8%ÀÇ ¾ÈÁ¤ÀûÀÎ ¼ºÀå¼¼¸¦ º¸¿´½À´Ï´Ù. °æÁ¦ ºÒȲÀº ´Ù¸¥ ½ÃÀå¿¡ ºñÇØ µ¿¹°¿ëÀǾàǰ »ê¾÷¿¡´Â »ó´ëÀûÀ¸·Î ´ú ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. Äڷγª19´Â µ¿¹°º´¿ø°ú ¼öÀÇ»çÀÇ ºñÁî´Ï½º ¸ðµ¨¿¡ ¸î °¡Áö º¯È­¸¦ °¡Á®¿Ô½À´Ï´Ù. ÀüÅëÀûÀÎ µ¿¹°º´¿øÀº »ý¹°ÇÐÀû Á¦Á¦³ª ÀǾàǰ°ú °°Àº °í¼öÀÍ Á¦Ç° ÆÇ¸Å¿¡¼­ °¡Àå ¸¹Àº ¼öÀÍÀ» ¿Ã¸± °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ƯÈ÷ ¹Ý·Á°ßÀÇ ¾Ï Áõ°¡´Â ½ÃÀå¿¡ ¼ºÀå ±â¹ÝÀ» Á¦°øÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¹Ì±¹¼öÀÇ»çȸ(AVMA)¿¡ µû¸£¸é, °³ 4¸¶¸® Áß 1¸¶¸®´Â ÀÏ»ý Áß ¾î´À ½ÃÁ¡¿¡ ½Å»ý¹°ÀÇ Â¡Èĸ¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½Å»ý¹°Àº °³¿¡¼­ ÈçÈ÷ º¼ ¼ö ÀÖ´Â ¾ÏÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. ÅëÁõ °ü¸®´Â °³ ½Å»ý¼ö󸮿¡¼­ °¡Àå Áß¿äÇÑ Ãø¸é Áß ÇϳªÀÔ´Ï´Ù. ÀÌ´Â ´ÜŬ·Ð Ç×ü¸¦ ÅëÇÑ Ä¡·áµµ °¡´ÉÇÕ´Ï´Ù.

½ÃÀåÀº °æÀïÀÌ Ä¡¿­ÇÏ°í ¿©·¯ ´ë±â¾÷ÀÌ ÁøÀÔÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå¿¡ ¾öû³­ ±âȸ°¡ »ý°Ü³ª¸é¼­ ½ÃÀåÀÇ ´Ù¾çÇÑ ±â¾÷µéÀÌ ¼±µµ ±â¾÷À¸·Î ºÎ»óÇϱâ À§ÇØ ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 10¿ù Zoetis´Â µ¿¹°¿ë ´ÜÀÏŬ·ÐÇ×ü(mAbs)ÀÇ »ý»ê ´É·ÂÀ» Çâ»ó½Ã۱â À§ÇØ ¾ÆÀÏ·£µå¿¡ »õ·Î¿î °³¹ß ¹× Á¦Á¶ ´ÜÀ§¸¦ ÀμöÇß½À´Ï´Ù.

À̸¦ ÅëÇØ µ¿¹°¿ë Ä¡·á ¹ÙÀÌ¿À ÀǾàǰ Æ÷Æ®Æú¸®¿À°¡ °­È­µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ 2021³â 8¿ù, ¿¤¶ûÄڴ Ųµå·¹µå ¹ÙÀÌ¿À»çÀ̾𽺸¦ ¾à 4¾ï 4,400¸¸ ´Þ·¯¿¡ ÀμöÇß½À´Ï´Ù. À̸¦ ÅëÇØ ¿¤¶ûÄÚ´Â ÇǺΰú ½ÃÀå ÁøÀÔÀ» Áö¿øÇϰí, Á¦Ç° ÆÄÀÌÇÁ¶óÀÎÀ» º¸¿ÏÇϸç, »ý¹°ÇÐÀû Á¦Á¦ ¹× ´ÜŬ·Ð Ç×ü ¿¬±¸°³¹ß ¿ª·®À» °­È­Çß½À´Ï´Ù.

¶ÇÇÑ 2023³â 5¿ù, ¿¤¶ûÄÚ´Â ´ÜŬ·Ð Ç×ü¸¦ ÀÌ¿ëÇÑ Ä¡¸íÀûÀÎ °³ ÆÄº¸¹ÙÀÌ·¯½º Áúȯ¿¡ ´ëÇÑ È¹±âÀûÀÎ Ä¡·á¹ýÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ 1ȸ Á¤¸Æ Åõ¿©·Î ¹é½Å Á¢Á¾ À¯¹«¿¡ °ü°è¾øÀÌ º´µç °³¿Í °­¾ÆÁöÀÇ ÆÄº¸¹ÙÀÌ·¯½º·Î ÀÎÇÑ Áõ»óÀ» Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù.

µ¿¹° ÀÇ·á¿ë ´ÜÀÏŬ·ÐÇ×ü ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • µ¿¹°À¯Çüº°·Î´Â ¹Ý·Á°ßÀÇ ÀÔ¾ç Áõ°¡¿Í ¹Ý·Á°ßÀÇ Áúº´ Ä¡·á¸¦ À§ÇÑ ¿¬±¸°³¹ßÀÌ Áõ°¡ÇÔ¿¡ µû¶ó 2024³â¿¡´Â ¹Ý·Á°ß ºÎ¹®ÀÌ ¾ÐµµÀûÀÎ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ¿ëµµº°·Î´Â °³ ¾ÆÅäÇÇ ÇǺο°ÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ÇǺΰú ºÐ¾ß°¡ 2024³â 51.31% ÀÌ»óÀÇ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â µ¿¹°º´¿ø ºÎ¹®ÀÌ 2024³â ¾ÐµµÀûÀÎ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇߴµ¥, ÀÌ´Â µ¿¹°º´¿ø¿¡ ÷´Ü Ä¡·á ½Ã¼³ÀÌ Àֱ⠶§¹®ÀÔ´Ï´Ù.
  • ºÏ¹Ì´Â 2024³â ¾à 43.775%·Î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇߴµ¥, ÀÌ´Â ºÏ¹Ì¿¡ ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Á¸ÀçÇϱ⠶§¹®ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
    • ½ÃÀå ±âȸ ºÐ¼®
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦ ºÐ¼®
  • ¾÷°è ºÐ¼®
    • PorterÀÇ Five Forces ºÐ¼®
    • Æä½ºÅÚ
  • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
  • Á¦Ç° ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • °¡°Ý ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå µ¿¹° ÀÇ·á¿ë ´ÜÀÏŬ·ÐÇ×ü ½ÃÀå : µ¿¹° À¯Çüº° ÃßÁ¤, µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • µ¿¹° ÀÇ·á¿ë ´ÜÀÏŬ·ÐÇ×ü ½ÃÀå : µ¿¹° À¯Çüº° º¯µ¿ ºÐ¼®, 2024³â ¹× 2030³â
  • °³
  • ±âŸ

Á¦5Àå µ¿¹° ÀÇ·á¿ë ´ÜÀÏŬ·ÐÇ×ü ½ÃÀå : ¿ëµµ ÃßÁ¤, µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • µ¿¹° ÀÇ·á¿ë ´ÜÀÏŬ·ÐÇ×ü ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®, 2024³â ¹× 2030³â
  • ÇǺΰú ½ÃÀå
  • ÅëÁõ
  • ±âŸ

Á¦6Àå µ¿¹° ÀÇ·á¿ë ´ÜÀÏŬ·ÐÇ×ü ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚ ÃßÁ¤, µ¿Ç⠺м®

  • µ¿¹° ÀÇ·á¿ë ´ÜÀÏŬ·ÐÇ×ü ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚ º¯µ¿ ºÐ¼®, 2024³â ¹× 2030³â
  • µ¿¹°º´¿ø
  • ±âŸ

Á¦7Àå µ¿¹° ÀÇ·á¿ë ´ÜÀÏŬ·ÐÇ×ü ½ÃÀå : Áö¿ª ÃßÁ¤, µ¿Ç⠺м®

  • µ¿¹° ÀÇ·á¿ë ´ÜÀÏŬ·ÐÇ×ü ½ÃÀå : Áö¿ª º¯µ¿ ºÐ¼®, 2024³â ¹× 2030³â
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • µ§¸¶Å©
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • ½ÃÀå ÁøÃâ±â¾÷ ºÐ·ù
  • ±â¾÷ ½ÃÀå ÇöȲ ºÐ¼®/heap ¸Ê ºÐ¼®
  • ±â¾÷ °³¿ä
    • Zoetis Inc.
    • Boehringer Ingelheim Gmbh
    • Merck &Co., Inc.
    • Elanco
    • Virbac SA
    • Indian Immunologicals Ltd
  • Àü·« ¸ÅÇÎ
    • ÀμöÇÕº´(M&A)
    • ÆÄÆ®³Ê½Ê ¹× Çù¾÷
    • È®´ë
    • Á¦Ç° ¹ß¸Å
    • Á¦Ç° ½ÂÀÎ
    • ±âŸ
  • List of Other Players

Á¦9Àå Áß¿ä Æ÷ÀÎÆ®

LSH

Monoclonal Antibodies In Veterinary Health Market Growth & Trends:

The global monoclonal antibodies in veterinary health market size is estimated to reach USD 3.30 billion by 2030, expanding at a CAGR of 19.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing pet population coupled with the rising pet expenditure is expected to boost the market growth. Furthermore, the growing prevalence of canine atopic dermatitis will likely drive market growth over the forecast period.

Despite disruption due to the COVID-19 pandemic, the animal health industry witnessed a steady growth of 8% from 2019 to 2020. The economic downturn was relatively less impactful in the animal health industry compared to other markets. The pandemic created a few shifts in business models for veterinary practices and veterinarians. Traditional veterinary practices are expected to generate the most revenue from selling high-margin products like biologics and pharmaceuticals.

The growing incidences of cancer, especially in dogs, are anticipated to provide a growth platform for the market. According to the American Veterinary Medical Association (AVMA), around 1 out of every 4 dogs are expected to show signs of neoplasia at some point in their lives. Neoplasia is a common type of cancer in dogs. Pain management is one of the most important aspects of treating neoplasia in dogs. This can also be treated using the monoclonal antibody treatment.

The market is highly competitive and consists of several major players. With the emergence of immense opportunities in the market, various players in the market are making investments to emerge as leading players. For instance, in October 2021, Zoetis acquired a new development and manufacturing unit in Ireland to improve its production capabilities on veterinary Monoclonal Antibodies (mAbs).

This is anticipated to enhance its veterinary therapeutic biopharmaceuticals portfolio. Moreover, in August 2021, Elanco acquired Kindred Biosciences for approximately USD 444 million. This supported the company's access to the dermatology market, complemented its product pipeline, and enhanced R&D capabilities in biologics and monoclonal antibodies.

In addition, in May 2023, Elanco announced its breakthrough treatment for deadly canine parvovirus diseases using monoclonal antibodies. This single intravenous dose treats the signs caused by parvovirus in sick dogs and puppies regardless of their vaccination status.

Monoclonal Antibodies In Veterinary Health Market Report Highlights:

  • Based on animal type, the dog segment held the dominant revenue share in 2024 owing to the growing adoption of dogs as pets and increasing R&D targeting canine disease treatments
  • Based on the application, the dermatology segment accounted for the largest market share of over 51.31% in 2024, owing to the increasing prevalence of canine atopic dermatitis
  • The veterinary hospital segment accounted for a dominant market share in terms of end-user in 2024, owing to the availability of advanced treatment facilities in veterinary hospitals
  • The North America accounted for the largest market share of around 43.775% in 2024, owing to the presence of major market players in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
    • 1.2.1. Information Procurement
  • 1.3. Information or Data Analysis
  • 1.4. General Methodology
  • 1.5. Research Scope & Assumptions
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Bottom-Up & Hybrid Model
    • 1.7.3. CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Industry Analysis
    • 3.3.1. Porter's
    • 3.3.2. PESTEL
  • 3.4. Regulatory Framework
  • 3.5. Product Pipeline Analysis
  • 3.6. Pricing Analysis
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Monoclonal Antibodies In Veterinary Health Market: Animal Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Monoclonal Antibodies In Veterinary Health Market: Animal Type Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Dogs
    • 4.3.1. Dogs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Others
    • 4.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Monoclonal Antibodies In Veterinary Health Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Monoclonal Antibodies In Veterinary Health Market: Application Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Dermatology Market
    • 5.3.1. Dermatology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Pain
    • 5.4.1. Pain Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Monoclonal Antibodies In Veterinary Health Market: End User Estimates & Trend Analysis

  • 6.1. Monoclonal Antibodies In Veterinary Health Market: End User Movement Analysis, 2024 & 2030 (USD Million)
  • 6.2. Veterinary Hospitals
    • 6.2.1. Veterinary Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Others
    • 6.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Monoclonal Antibodies In Veterinary Health Market: Regional Estimates & Trend Analysis

  • 7.1. Monoclonal Antibodies In Veterinary Health Market: Regional Movement Analysis, 2024 & 2030
  • 7.2. North America
    • 7.2.1. North America Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. U.S. Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Canada Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Mexico Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. UK Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Germany Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. France Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Italy Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Spain Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Sweden
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Sweden Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Denmark
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Denmark Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Norway Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. China Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Japan Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. India Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Australia Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. South Korea Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Thailand Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Brazil Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Argentina Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East & Africa
    • 7.6.1. Middle East & Africa Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. South Africa Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Saudi Arabia Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. UAE Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Kuwait Monoclonal Antibodies In Veterinary Health Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Position Analysis/ Heap Map Analysis
  • 8.3. Company Profiles
    • 8.3.1. Zoetis Inc.
      • 8.3.1.1. Participant's Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Boehringer Ingelheim Gmbh
      • 8.3.2.1. Participant's Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Merck & Co., Inc.
      • 8.3.3.1. Participant's Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Elanco
      • 8.3.4.1. Participant's Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Virbac S.A.
      • 8.3.5.1. Participant's Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Indian Immunologicals Ltd
      • 8.3.6.1. Participant's Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
  • 8.4. Strategy Mapping
    • 8.4.1. Mergers & Acquisitions
    • 8.4.2. Partnerships & Collaborations
    • 8.4.3. Expansion
    • 8.4.4. Product launch
    • 8.4.5. Product Approval
    • 8.4.6. Others
  • 8.5. List of Other Players

Chapter 9. Key Takeaways

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦